Thomas Clozel

Dr. Thomas Clozel is a skilled Medical Doctor with a focus on integrating AI and system biology in the medical field.

He has a rich educational background including a research fellowship in Hematology-oncology from the Joan & Sanford I. Weill Medical College of Cornell University and clinical rotations in the Neurology Department at Icahn School of Medicine at Mount Sinai.

Dr. Clozel has been associated with various prominent organizations such as XPRIZE, Université Paris-Saclay, Cure51, Bioptimus, GRACE, Sofinnova Partners, and OWKIN where he served as the Chief Executive Officer and Co-founder.

His contributions also extend to investments and advisory roles in companies like Fragment, Osium AI, 8400 The Health Network, Kanji, Dioxycle, Spot, Resilience care, and Patch Biosciences.

Prior to his entrepreneurial ventures, Dr. Clozel served as a Clinical Assistant Professor at CHU Henri Mondor de Créteil and gained experience as a Research Fellow at Weill Cornell Medical College.

He holds a Master 2 parcours recherche in Biochimie, Cellules, Cibles Thérapeutiques (BC2T) and has completed internships and rotations at reputable medical centers like Hôpital Necker-Enfants Malades and Mount Sinai Medical Center.